ASA Makes Recommendations to FDA for Opioid Conversion Labeling

In a letter to the FDA, the American Society of Anesthesiologists has addressed public health concerns associated with the use of equianalgesic opioid conversion tables and has recommended a staged approach for opioid conversion labeling.  

Advertisement

According to ASA, “opioid conversion must emphasize the goal of safety by specifying the potential for dose adjustments after calculation of the equianalgesic dose.”

Download the full letter on the ASA website.

More Articles on Anesthesia:

Study: Prescription Painkiller Overdose Deaths in Women Spike 400% in 10 Years
Dr. Walter Schuyler Joins Pain Specialists of Charleston

Sibley Medical Center to Open Pain Management Clinic, Adds Dr. J. Richard Waggoner

Advertisement

Next Up in Anesthesia

  • Workforce shortages, reimbursement declines and costly inefficiencies were some of the biggest anesthesia-related issues for ASC leaders in 2025. While…

  • As physician employment accelerates, anesthesia leaders say the biggest pressure points are structural rather than clinical. Anesthesiologist Jason Hennes, MD,…

Advertisement

Comments are closed.